A supplement meant to ease joint pain may be accelerating dementia
For decades, glucosamine has sat quietly in medicine cabinets as a trusted remedy for aching joints — cheap, natural, and seemingly harmless. Now, researchers at the University of Florida have surfaced a troubling possibility: that this common supplement may cross into the brain and accelerate the very cognitive decline that millions of aging Americans are already fighting. The study does not yet prove causation, but it asks a question that can no longer be ignored — what hidden costs might our most familiar remedies carry?
- A University of Florida study found glucosamine users with mild cognitive impairment were 25% more likely to develop full Alzheimer's — and those already diagnosed faced a 25% higher risk of death.
- The supplement, trusted for decades as a safe joint remedy, may cross the blood-brain barrier and trigger an overactive sugar-tagging of proteins, potentially feeding the toxic plaques and tangles that define Alzheimer's disease.
- Mouse models confirmed the pattern — glucosamine increased protein sugar-attachment and caused memory deficits, while suppressing that process restored memory function.
- With roughly 7 million Americans living with Alzheimer's and millions more taking glucosamine daily, the overlap between these two populations represents an urgent and largely unexamined clinical risk.
- Researchers are not calling for an immediate halt but are urging patients with cognitive concerns to consult their doctors, while pushing for metabolic interventions to complement existing plaque-focused treatments.
Millions of Americans take glucosamine each year to ease joint pain — it is cheap, widely available, and long considered safe. But a June 2026 study published in Nature Metabolism by University of Florida researchers suggests the supplement may carry a hidden cost, not to the joints, but to the brain.
Analyzing health records from 2012 to 2024 and using artificial intelligence to identify patients with cognitive decline, the team found that glucosamine users with mild cognitive impairment were 25% more likely to progress to full dementia. Among those already diagnosed with Alzheimer's, glucosamine users faced a 25% higher mortality risk. About 8% of cognitively impaired patients in the dataset were taking the supplement.
The proposed mechanism centers on "sugar-tagging" — a process by which sugar molecules attach to proteins to help them fold and function correctly. In a healthy brain, this system operates in balance. In Alzheimer's disease, the researchers found, it becomes overactive. Glucosamine, which can cross the blood-brain barrier, appears to amplify this imbalance, potentially contributing to the formation of amyloid plaques and tau tangles that are hallmarks of the disease.
Experiments with genetically modified mice reinforced the theory: glucosamine increased protein sugar-attachment and produced memory deficits, while suppressing the process improved memory. Human brain tissue from Alzheimer's patients showed the same elevated sugar-tagging pattern.
Lead researcher Ramon Sun described the findings as pointing toward metabolism as an underappreciated driver of Alzheimer's progression, suggesting that targeting this pathway could complement existing treatments. Biochemist Matt Gentry was careful to note the study shows association, not causation — but called the question one that now demands serious clinical attention. For anyone navigating both joint pain and cognitive decline, the familiar bottle on the shelf may warrant a second look.
Millions of Americans reach for glucosamine supplements each year, hoping to ease the ache in their knees and hips. The over-the-counter remedy is cheap, widely available, and has become a standard fixture in medicine cabinets for anyone dealing with joint pain. But a study published in June by researchers at the University of Florida suggests that this familiar supplement may carry a hidden cost—one that affects not the joints, but the brain.
The research, released in the journal Nature Metabolism, found that people taking glucosamine were 25% more likely to progress from mild cognitive impairment to full dementia and Alzheimer's disease. Among those already diagnosed with Alzheimer's, glucosamine users faced a 25% higher risk of death. The findings come from an analysis of the University of Florida's health care system spanning 2012 to 2024, where researchers used artificial intelligence to identify patients with cognitive decline. Nearly one in ten of those patients—about 8%—were taking glucosamine supplements.
Glucosamine itself is a natural compound found in healthy cartilage, the tissue that cushions joints. The supplement is designed to reduce inflammation and protect the cells that maintain cartilage structure. For decades, it has been marketed as a safe, natural way to manage joint pain. But the Florida team discovered something troubling: glucosamine can cross the blood-brain barrier, the protective membrane that separates the brain from the rest of the body. Once there, it may interfere with how the brain processes proteins.
The mechanism appears to involve what researchers call "sugar-tagging"—a process where sugar molecules attach to proteins so they fold correctly, travel to the right place, and perform their intended functions. In a healthy brain, this system works in balance. But in Alzheimer's disease, the researchers found, this sugar-tagging system becomes overactive. The brain adds too many sugar structures to proteins, and this excess appears to contribute to the disease rather than protect against it. The result may be the formation of toxic protein deposits—amyloid plaques and tau tangles—that are hallmarks of Alzheimer's pathology.
To test this theory, the team worked with genetically modified mice. When given glucosamine, these mice showed significantly increased sugar attachment to proteins in their cells and developed memory deficits. When researchers suppressed the sugar-tagging process, the mice's memory improved. The team also examined human brain tissue from the University of Florida's Neuromedicine Brain and Tissue Bank and found the same pattern of increased sugar attachment in specimens from Alzheimer's patients.
Matt Gentry, chair of biochemistry and molecular biology at the University of Florida, emphasized that the study shows an association, not proof of causality. "While it's an association and not proof of causality, it does raise an important clinical question that now deserves much more attention," he said. Yet the implications are stark. In the United States alone, roughly 7 million people are living with Alzheimer's disease, and millions more have related dementias such as Lewy body or frontotemporal dementia. Many of these patients are actively taking an over-the-counter supplement that could be accelerating their cognitive decline.
Ramon Sun, senior researcher and director of the Center for Advanced Spatial Biomolecule Research at the University of Florida, sees the findings as pointing toward a new avenue for treatment. "Our results suggest that altered metabolism is a significant contributor to Alzheimer's progression," he said, "and addressing the metabolic defect could be an important complement to approaches focused on Alzheimer's plaques and tangles." The study does not recommend that people stop taking glucosamine immediately, but it does suggest that anyone with cognitive concerns should discuss the supplement with their doctor. For millions of people managing both joint pain and cognitive decline, the choice may no longer be as simple as reaching for the bottle.
Citas Notables
While it's an association and not proof of causality, it does raise an important clinical question that now deserves much more attention.— Matt Gentry, chair of biochemistry and molecular biology at the University of Florida
A lot of these people actively take an over-the-counter supplement that could be making their disease progression worse.— Ramon Sun, director of the Center for Advanced Spatial Biomolecule Research at the University of Florida
La Conversación del Hearth Otra perspectiva de la historia
Why would a joint supplement affect the brain at all? That seems like two separate systems.
Glucosamine is a sugar-based molecule, and it can cross the blood-brain barrier—the protective wall that usually keeps most substances out. Once it's in the brain, it participates in a process that's already going wrong in Alzheimer's patients.
The sugar-tagging thing. Can you explain that more simply?
Proteins need sugar molecules attached to them in order to work correctly—to fold the right way, to get to the right place in the cell. In a healthy brain, this happens in balance. But in Alzheimer's brains, this process is already overactive. Adding more glucosamine seems to make it worse.
So it's not that glucosamine causes Alzheimer's. It's that it makes an existing problem worse.
Exactly. The study shows an association, not causation. But if you already have mild cognitive impairment or Alzheimer's, taking glucosamine appears to speed up the disease and increase the risk of death.
How many people are we talking about?
About 7 million Americans have Alzheimer's, and millions more have related dementias. The researchers found that roughly 8% of patients with cognitive decline in their health system were taking glucosamine. That's a lot of people potentially making their condition worse without knowing it.
What should someone do if they're taking glucosamine and worried about this?
Talk to their doctor. The study doesn't say to stop immediately, but it does raise a serious enough question that it deserves a conversation with a physician, especially if someone has any signs of cognitive decline.